Lupin (Europe)

Company snapshot

Lupin Europe is a pharma organization headquartered in EU. Primary therapeutic focus areas include Myotonic Dystrophy type 1 and type 2 (DM1/DM2), Non-Dystrophic Myotonias (NDM). NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (3), approved (1).

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Lupin (Europe). Not investment advice.

• What is Lupin (Europe)?

  Lupin Europe is a pharma organization headquartered in EU. Primary therapeutic focus areas include Myotonic Dystrophy type 1 and type 2 (DM1/DM2), Non-Dystrophic Myotonias (NDM). NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity

• Is Lupin (Europe) publicly traded?

  Lupin (Europe) appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Lupin (Europe) develop or market?

  We link 9 drug profile(s) where Lupin (Europe) is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/lupin-europe-gmbh#company-drugs.

• What are the latest developments for Lupin (Europe)?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Lupin (Europe) focus on?

  Lupin (Europe) focuses on Myotonic Dystrophy type 1 and type 2 (DM1/DM2), Non-Dystrophic Myotonias (NDM) based on our analysis of their pipeline programs and drug development activities.